Payment overview · 2025
General Payments
$481.62
25 reported records · 9 companies
Healthcare provider profile · identity verified
Jack W Cramer, DO
Allopathic & Osteopathic Physicians|Family Medicine · ELYRIA, OH · NPI 1134331440
Verified facts
What the public records show
CMS Open Payments records show Jack W Cramer, DO received $481.62 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.06 | 36.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.48 | 14.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $60.87 | 12.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.23 | 11.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.20 | 11.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.39 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.17 | 3.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.19 | 3.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.03 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.62 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $176.06 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.48 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $60.87 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.20 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 267 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 62 |
| Prednisone | Prednisone | 234 | 88 |
| Metformin Hcl | Metformin Hcl | 192 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 149 | 39 |
| Simvastatin | Simvastatin | 149 | 42 |
| Furosemide | Furosemide | 133 | 47 |
| Lisinopril | Lisinopril | 118 | 34 |
| Losartan Potassium | Losartan Potassium | 118 | 34 |
| Clonazepam | Clonazepam | 117 | 16 |
| Gabapentin | Gabapentin | 107 | 35 |
| Omeprazole | Omeprazole | 100 | 24 |
| Allopurinol | Allopurinol | 94 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 25 |
| Azithromycin | Azithromycin | 87 | 65 |
| Buspirone Hcl | Buspirone Hcl | 75 | 20 |
| Meloxicam | Meloxicam | 75 | 24 |
| Glimepiride | Glimepiride | 70 | 20 |
| Spironolactone | Spironolactone | 70 | 16 |
| Glipizide | Glipizide | 68 | 11 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 12 |
| Jardiance | Empagliflozin | 64 | 11 |
| Ibuprofen | Ibuprofen | 61 | 27 |
| Methylprednisolone | Methylprednisolone | 61 | 45 |
| Amoxicillin | Amoxicillin | 58 | 42 |
| Alprazolam | Alprazolam | 55 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 35 |
| Trazodone Hcl | Trazodone Hcl | 51 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Montelukast Sodium | Montelukast Sodium | 41 | 16 |
| Levofloxacin | Levofloxacin | 40 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 11 |
| Eliquis | Apixaban | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 13 |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 15 |
| Finasteride | Finasteride | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Ozempic | Semaglutide | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Sertraline Hcl | Sertraline Hcl | 29 | 11 |
| Cephalexin | Cephalexin | 27 | 25 |
| Famotidine | Famotidine | 26 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 16 |
| Metronidazole | Metronidazole | 17 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Diazepam | Diazepam | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.62 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAMZYOS, Cologuard Collection Kit, Dexcom G6 Transmitter, GVOKE HYPOPEN, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error